S&P 5007,765.36▼0.5% Nasdaq27,193.34▼1.2% Dow51,231.64▲0.1% Russell 2K2,794.13▲0.0% 10-Yr5.23%−5bp VIX15.41+0.33 WTI$91.10▲3.2% Gold$4,157.80▲0.4% EUR/USD1.122▼0.3% BTC$81,907▼1.4% Nikkei70,036▼0.9%
At close · Thu, Oct 8, 2026
Daily Market Updates.

US Markets

Home›US Markets›M&A & Deals›AstraZeneca weighs a possible merger with Bristol Myer…

AstraZeneca weighs a possible merger with Bristol Myers Squibb

The talks, described by the Financial Times, would involve a deal valued at about $400 billion.

Reported · Written up by our desk · M&A & Deals

AstraZeneca is reported to be considering a merger with U.S. rival Bristol Myers Squibb, according to coverage cited by CNBC.

The Financial Times has said the potential combination would be on a mega scale, with a suggested value around $400 billion.

Both outlets frame the development as discussions around a possible merger, with no final terms or outcome reported in the available summary.

← Newer storySenate floor schedule omits CLARITY Act as clock nears Aug. recess

More like this

US MarketsSEC proposals would shift power away from retail investors
US MarketsApple launches HomeView smart home hub with upgraded Siri AI
US MarketsIthaca Holdings to buy Bumble for $1.3 billion
US MarketsPoundland in talks with buyers as management seeks buyout
US MarketsTFG London investigates cyber incident affecting Phase Eight, Hobbs and Whistles

Sources

CNBC MarketsAstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports
CNBC WorldAstraZeneca in talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

Get the close, explained.

One email every trading day: what moved, why it moved, and what's on deck tomorrow. Read in 3 minutes.

Free. Unsubscribe anytime.